ArticleFrontiers in immunology2022
CD11c
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Graves' disease following immunosuppression withdrawal and SARS-CoV-2 infection in a failed kidney allograft recipient: a case report on immune reconstitution.Frontiers in immunology · 2026Article
- The gut microbiota in Graves' disease: mechanistic insights and clinical implications.Frontiers in cellular and infection microbiology · 2026Review
- The multiple functions of CD5 in diseases related to immune disorders.Annals of medicine · 2025Review
- Review
- The immune tolerance role of Bregs in inhibiting human inflammatory diseases, with a focus on diabetes mellitus.Frontiers in immunology · 2025Review
- Subtype-specific atypical B cell profiles in myasthenia gravis reveal distinct immunopathological pathways.Frontiers in immunology · 2025Article
- Epstein-Barr virus in thyroid disease: an integrated immunovirological perspective.Frontiers in immunology · 2025Review
- Emerging insights into atypical B cells in pediatric chronic infectious diseases and immune system disorders: T(o)-bet on control of B-cell immune activation.The Journal of allergy and clinical immunology · 2024Review
- Characterizing the Interplay of Lymphocytes in Graves' Disease.International journal of molecular sciences · 2023Review
- High levels of thyroid hormones promote recurrence of Graves' disease via overexpression of B-cell-activating factor.Journal of clinical laboratory analysis · 2022Article
- The peripheral and decidual immune cell profiles in women with recurrent pregnancy loss.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graves' disease (GD) is a common autoimmune disorder with an elevation in pathogenic autoantibodies, specifically anti-thyrotropin receptor antibodies (TRAbs), which are secreted by autoreactive B cells. To date, there has been little research on self-reactive B cells in GD. In the current study, we reported that a unique B-cell subset, CD11c
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.